Trial Profile
A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiveing Myelotoxic Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Efbemalenograstim alfa (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Evive Biotech; Generon (Shanghai) Corporation
- 22 Feb 2018 Status changed from recruiting to completed.
- 18 Aug 2015 New trial record